This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Betz, U. A. K.
Right arrow Articles by Rübsamen-Waigmann, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betz, U. A. K.
Right arrow Articles by Rübsamen-Waigmann, H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2002, p. 1766-1772, Vol. 46, No. 6
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.6.1766-1772.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Potent In Vivo Antiviral Activity of the Herpes Simplex Virus Primase-Helicase Inhibitor BAY 57-1293

Ulrich A. K. Betz,* Rüdiger Fischer, Gerald Kleymann, Martin Hendrix, and Helga Rübsamen-Waigmann

Bayer AG, Pharma Research Antiinfectives, Wuppertal, Germany

Received 24 October 2001/ Returned for modification 17 January 2002/ Accepted 11 March 2002

BAY 57-1293 belongs to a new class of antiviral compounds and inhibits replication of herpes simplex virus (HSV) type 1 and type 2 in the nanomolar range in vitro by abrogating the enzymatic activity of the viral primase-helicase complex. In various rodent models of HSV infection the antiviral activity of BAY 57-1293 in vivo was found to be superior compared to all compounds currently used to treat HSV infections. The compound shows profound antiviral activity in murine and rat lethal challenge models of disseminated herpes, in a murine zosteriform spread model of cutaneous disease, and in a murine ocular herpes model. It is active in parenteral, oral, and topical formulations. BAY 57-1293 continued to demonstrate efficacy when the onset of treatment was initiated after symptoms of herpetic disease were already apparent.

* Corresponding author. Mailing address: Bayer AG, International Pharma Research, PH-R-EU, Geb. 402, Aprather Weg 18a, D-42096 Wuppertal, Germany. Phone: 49-(0)202-364974. Fax: 49-(0)202-368171. E-mail: ulrich.betz.ub{at}bayer-ag.de.

Antimicrobial Agents and Chemotherapy, June 2002, p. 1766-1772, Vol. 46, No. 6
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.6.1766-1772.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Chen, Y., Livingston, C. M., Carrington-Lawrence, S. D., Bai, P., Weller, S. K. (2007). A Mutation in the Human Herpes Simplex Virus Type 1 UL52 Zinc Finger Motif Results in Defective Primase Activity but Can Recruit Viral Polymerase and Support Viral Replication Efficiently. J. Virol. 81: 8742-8751 [Abstract] [Full Text]  
  • Chen, Y., Carrington-Lawrence, S. D., Bai, P., Weller, S. K. (2005). Mutations in the Putative Zinc-Binding Motif of UL52 Demonstrate a Complex Interdependence between the UL5 and UL52 Subunits of the Human Herpes Simplex Virus Type 1 Helicase/Primase Complex. J. Virol. 79: 9088-9096 [Abstract] [Full Text]  
  • Liao, G., Huang, J., Fixman, E. D., Hayward, S. D. (2005). The Epstein-Barr Virus Replication Protein BBLF2/3 Provides an Origin-Tethering Function through Interaction with the Zinc Finger DNA Binding Protein ZBRK1 and the KAP-1 Corepressor. J. Virol. 79: 245-256 [Abstract] [Full Text]  
  • De Clercq, E. (2003). New inhibitors of human cytomegalovirus (HCMV) on the horizon. J Antimicrob Chemother 51: 1079-1083 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»